BTNX Inc.

BTNX Inc. is a leading biotechnology company established in 1996, headquartered in Pickering, Ontario, Canada. Specialized in point-of-care diagnostic solutions, BTNX develops, manufactures, and distributes advanced in-vitro diagnostic tests for laboratories, clinics, and hospitals worldwide. The company's Rapid Response® product line includes rapid diagnostic tests for infectious diseases (COVID-19, influenza), drug screening (fentanyl, xylazine, medetomidine), urinalysis, women's health, and cancer screening. BTNX also manufactures harm reduction testing kits and develops HL7/POCT1-A2 compliant IT systems for test result management. All products are manufactured in ISO 13485:2016 MDSAP-certified facilities and meet CE and FDA standards. The company's diagnostic portfolio reaches over 135 countries and serves healthcare providers, laboratories, and community organizations with both clinical and forensic-use testing solutions.